US20070111964A1 - Vitamin B12 nasal spray and method of use - Google Patents
Vitamin B12 nasal spray and method of use Download PDFInfo
- Publication number
- US20070111964A1 US20070111964A1 US11/506,148 US50614806A US2007111964A1 US 20070111964 A1 US20070111964 A1 US 20070111964A1 US 50614806 A US50614806 A US 50614806A US 2007111964 A1 US2007111964 A1 US 2007111964A1
- Authority
- US
- United States
- Prior art keywords
- set forth
- cobalamin compound
- dose
- aqueous composition
- cobalamin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7135—Compounds containing heavy metals
- A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
- A61M11/006—Sprayers or atomisers specially adapted for therapeutic purposes operated by applying mechanical pressure to the liquid to be sprayed or atomised
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/08—Inhaling devices inserted into the nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
Definitions
- the present invention relates generally to vitamin B 12 nasal spray compositions and methods of using the same in the treatment of vitamin B 12 deficiency and various disorders that are related to such deficiency.
- the present invention is directed to treatment methods comprising intranasal administration of a cobalamin composition according to a particular dosing and frequency schedule and to a preservative-free nasal spray composition comprising a cobalamin compound useful in the practice of such treatment methods.
- Vitamin B 12 is a water soluble vitamin that plays a role in mammalian growth, hematopoiesis, production of epithelial cells, and maintenance of the nervous system. It was first isolated from liver concentrate in 1948 and structurally elucidated in the late 1950's.
- Cyanocobalamin is a form of vitamin B 12 and is one of the class of B 12 vitamins or cobalamin compounds that includes vitamin B 12a (hydroxocobalamin), vitamin B 12b (aquacobalamin), vitamin B 12c (nitrilocobalamin), methyl B 12 (methylcobalamin) and coenzyme B 12 (5′deoxyadenosine cobalamin).
- Cyanocobalamin and hydroxocobalamin are the principal members of the class and the most widely employed in compositions used to treat vitamin B 12 deficiency and disorders that are related to this deficiency. Such disorders include anemias (most commonly pernicious anemia) and diphyllobothrium latum (fish tapeworm) infestation of the intestine, a disorder with symptomology that mimics pernicious anemia.
- vitamin B 12 Several routes of administration of vitamin B 12 are known. Among these are parenterally, including intramuscular and subcutaneous injection, orally as a component of a tablet or solution, and nasally, as a component of a nasal spray or gel. Although the minimum daily dietary requirement of vitamin B 12 is approximately 0.1 ⁇ g for a healthy human, therapeutic administration of vitamin B 12 is typically in significantly larger doses. For example, the prescribed initial therapeutic dose is generally from about 100 ⁇ g to about 1000 ⁇ g, and is most often administered by intramuscular injection. Subsequent vitamin B 12 maintenance therapy may be by injection or by oral administration of a cobalamin composition. Use of vitamin B 12 injections for maintenance therapy has obvious disadvantages, including the inconvenience and pain associated with the injection that typically must be administered by medical personnel. Orally administered cobalamin compositions may fail to be adequately absorbed in the patient, particularly in those in which secretion or utilization of intrinsic factor is inadequate.
- Intranasal administration of cobalamin compositions for vitamin B 12 maintenance therapy offers advantages over these alternative routes of administration.
- such therapy includes relatively infrequent, high dose nasal administration of a cobalamin composition.
- NASCOBAL nasal spray solution containing 0.5% by weight cyanocobalamin is administered in one nostril once weekly in a dose of 500 ⁇ g (i.e., 500 ⁇ g cyanocobalamin per 0.1 mL actuation of the spray bottle pump).
- vitamin B 12 nasal compositions Although maintenance therapy with vitamin B 12 nasal compositions has proven generally effective, those undergoing such therapy may experience some irritation of the nasal mucosa and discomfort due, in part, to the high dosage of the cobalamin compound typically administered as well as preservatives and other additives often present in these compositions. Moreover, effective vitamin B 12 maintenance therapy would be enhanced if more stable or even blood serum levels of vitamin B 12 could be attained through intranasal administration of a cobalamin composition. Accordingly, a need persists for improvements in vitamin B 12 nasal compositions and methods of nasal administration of such compositions in the treatment of vitamin B 12 deficiency and various vitamin B 12 deficiency-mediated disorders.
- the present invention is directed to a method for maintaining vitamin B 12 blood serum levels in a mammals, the method comprising nasally administering to the mammal at least once every three days an aqueous composition comprising a cobalamin compound in an amount sufficient to deliver a dose of no more than about 150 ⁇ g of the cobalamin compound to the mammal.
- the present invention is further directed to a method for maintaining normal hematologic status in a pernicious anemia patient following intramuscular vitamin B 12 injection therapy, the method comprising nasally administering to said patient at least once every three days an aqueous composition comprising a cobalamin compound in an amount sufficient to deliver a dose of no more than about 150 ⁇ g of the cobalamin compound to the patient.
- the present invention is further directed to a composition for nasal administration of a cobalamin compound, the composition comprising an aqueous solution containing a cobalamin compound and a pharmaceutically acceptable buffer, the composition having a pH of at least about 6.5.
- the present invention is further directed to a composition for nasal administration of a cobalamin compound, the composition comprising an aqueous solution containing a cobalamin compound and a pharmaceutically acceptable buffer and being free of preservatives.
- FIG. 1 depicts the mean serum vitamin B 12 levels and 95% confidence interval for all six visits in the study conducted in the Example.
- the present invention is based in part on the observation that conventional intranasal administration of cobalamin compositions may lead to irritation of the nasal membranes or mucosa. Irritation may be caused or exacerbated by the relatively high dose of cobalamin compound typically administered and/or preservatives and other additives commonly contained in these compositions. This irritation, compounded by infrequent, high dose administration of conventional intranasal cobalamin compositions (e.g., anywhere from once a week to as rarely as once a month), can lead to patient noncompliance and variable blood serum vitamin B 12 levels and ultimately to inconsistent or ineffective treatment of vitamin B 12 deficiency-mediated disorders.
- the present invention is directed to methods for maintaining vitamin B 12 blood serum levels in a mammal comprising more frequent intranasal administration of a cobalamin composition and at lower dosages than previously recognized as effective in the treatment of such disorders.
- the present invention further provides compositions containing a cobalamin compound useful in the practice of the treatment methods disclosed herein, while minimizing the risk of irritation of the nasal mucosa and patient noncompliance with the prescribed treatment regimen.
- the treatment methods disclosed herein are generally applicable for maintenance of vitamin B 12 blood serum levels in a patient in need of vitamin B 12 therapy.
- a patient may be suffering from a vitamin B 12 deficiency, a disorder resulting from such a deficiency, or a disorder mimicking the symptomology of such a deficiency.
- disorders resulting from or mimicking a vitamin B 12 deficiency include, for example, anemia, including pernicious anemia; nerve degeneration, typically as a result of degradation or lack of myelin; and infestation by intestinal parasites or bacteria such as diphyllobothrium latum (fish tapeworm) that absorb large quantities of vitamin B 12 in the host.
- vitamin B 12 malabsorption phenomena such as that resulting from inadequate secretion and/or utilization of intrinsic factor (e.g., due to HIV infection, AIDS, Crohn's disease, tropical and nontropical sprue, extensive neoplasia, subtotal or total gastrectomy, etc.); maintenance of vitamin B 12 in excess of normal dietary requirements due to pregnancy, renal disease, thyrotoxicosis, hemolytic anemia, hemorrhage, etc; and patients having elevated serum homocysteine, cystathionine, methylmalonic acid and/or 2-methylcitric acid levels.
- the present invention is directed particularly to the treatment of humans in need of vitamin B 12 therapy.
- the methods disclosed herein are generally applicable to the treatment of mammals including, for example, domesticated house pets, such as dogs and cats, as well as farm animals, such as cattle, pigs, horses, sheep and goats.
- the treatment methods of the present invention comprise more frequent and lower dose intranasal administration of a composition containing a cobalamin compound. It has been discovered that more frequent and lower dose intranasal administration of a cobalamin composition offers several advantages over conventional intranasal vitamin B 12 maintenance therapy, including reduced risk of irritation of the nasal mucosa and more stable or even vitamin B 12 blood serum levels (i.e., smaller peak to trough variances) by more closely mimicking the typical mammalian dietary intake of vitamin B 12 . Moreover, it is believed that patient compliance is improved by treatment regimens including more frequent administration of the cobalamin composition.
- compositions used in the practice of the methods disclosed herein include, for example, aqueous solutions of the cobalamin compound along with various optional components such as isotonicity agents, buffering agents, humectants, surfactants and preservatives.
- the treatment method for maintaining vitamin B 12 blood serum levels in a mammal in accordance with the present invention comprises nasally administering to the mammal an aqueous composition comprising a cobalamin compound at least once every three days, preferably at least once every two days.
- the frequency of administration may vary during the treatment period.
- the composition may be administered every day during an initial portion (e.g., the first week or first two weeks) of the treatment period (e.g., daily during an initial “loading” period to increase vitamin B 12 blood serum levels), and then at less frequent intervals during the remainder of the treatment period.
- administration preferably occurs at regular intervals throughout the treatment period.
- the treatment method of the present invention comprises daily intranasal administration (i.e., one or more administrations per day), and especially once daily, intranasal administration of the cobalamin composition during the treatment period.
- the dose of the cobalamin compound delivered to the patient with each administration will vary generally with the frequency of administration (a higher dose being utilized with longer intervals between administrations), as well as with the needs of the patient and the type of disorder being treated, as would be apparent to those skilled in the art, but is generally lower than the dosing conventionally employed.
- the dose of the cobalamin compound delivered to the patient with each administration is no more than about 150 ⁇ g, preferably no more than about 125 ⁇ g, more preferably no more than about 100 ⁇ g, and still more preferably no more than about 75 ⁇ g of the cobalamin compound, and is at least 5 ⁇ g, preferably at least about 10 ⁇ g of the cobalamin compound.
- the daily dose of the cobalamin compound delivered to the patient is preferably from about 5 ⁇ g to about 100 ⁇ g, more preferably from about 20 ⁇ g to about 80 ⁇ g, still more preferably from about 30 ⁇ g to about 70 ⁇ g and even more preferably from about 40 ⁇ g to about 60 ⁇ g.
- the dose of the cobalamin compound delivered to the patient with each administration is usually no more than about 80 ⁇ g.
- the dose of the cobalamin compound delivered to the patient with each administration is preferably from about 5 ⁇ g to about 80 ⁇ g, more preferably from about 10 ⁇ g to about 60 ⁇ g, more preferably from about 15 ⁇ g to about 50 ⁇ g, more preferably from about 20 ⁇ g to about 50 ⁇ g, more preferably from about 30 ⁇ g to about 50 ⁇ g, still more preferably from about 40 ⁇ g to about 50 ⁇ g and even more preferably from about 45 ⁇ g to about 50 ⁇ g.
- the dose of the cobalamin compound delivered to the patient per administration may be about 10 ⁇ g, about 15 ⁇ g, about 20 ⁇ g, about 25 ⁇ g, about 30 ⁇ g, about 35 ⁇ g, about 40 ⁇ g, about 45 ⁇ g, or about 50 ⁇ g.
- the dose of the cobalamin compound delivered to the patient with each administration is from about 5 ⁇ g to about 45 ⁇ g, preferably from about 10 ⁇ g to about 45 ⁇ g, more preferably from about 15 ⁇ g to about 45 ⁇ g, more preferably from about 20 ⁇ g to about 45 ⁇ g, still more preferably from about 30 ⁇ g to about 45 ⁇ g, and even more preferably from about 40 ⁇ g to about 45 ⁇ g.
- each administration may comprise one or a plurality of applications or sprays of the cobalamin composition delivered to the nasal mucosa of the patient through one or both nostrils, the number of applications or sprays being dependent upon the concentration of the cobalamin compound in the composition, the quantity of the composition delivered per spray, and the desired dose per administration as readily determined by one skilled in the art.
- the cobalamin composition is preferably dispensed from a spray bottle including a pump (e.g., a manually actuated pump) capable of delivering a metered spray of the cobalamin composition of predetermined volume (typically about 0.1 mL).
- a daily dose of 50 ⁇ g of a cobalamin compound may be administered in a single administration comprising one or more applications or metered sprays containing a total of 50 ⁇ g of cobalamin compound (e.g., a single administration comprising two applications or metered sprays, one in each nostril and each containing 25 ⁇ g of cobalamin compound) or in multiple administrations (e.g., four administrations at six hour intervals, each administration comprising one or more applications or metered sprays, in one or both nostrils, each administration containing a total of 12.5 ⁇ g of cobalamin compound).
- a single administration comprising two applications or metered sprays, one in each nostril and each containing 25 ⁇ g of cobalamin compound
- multiple administrations e.g., four administrations at six hour intervals, each administration comprising one or more applications or metered sprays, in one or both nostrils, each administration containing a total of 12.5 ⁇ g of cobalamin compound.
- the weekly dose of the cobalamin compound received by the patient will generally not be in excess of about 1000 ⁇ g, more preferably about 800 ⁇ g, still more preferably about 600 ⁇ g, even more preferably about 500 ⁇ g, still more preferably about 450 ⁇ g, even more preferably about 400 ⁇ g, and most preferably not in excess of about 350 ⁇ g of the cobalamin compound. Accordingly, in one embodiment, the patient may receive a weekly dosage of from about 50 ⁇ g to about 500 ⁇ g of the cobalamin compound. In another embodiment, the patient may receive a weekly dosage of from about 100 ⁇ g to about 450 ⁇ g of the cobalamin compound.
- the patient may receive a weekly dosage of from about 150 ⁇ g to about 400 ⁇ g of the cobalamin compound. In still another embodiment, the patient may receive a weekly dosage of from about 200 ⁇ g to about 400 ⁇ g of the cobalamin compound. In yet another embodiment, the patient may receive a weekly dosage of from about 250 ⁇ g to about 350 ⁇ g of the cobalamin compound. In still another embodiment, the patient may receive a weekly dosage of from about 300 ⁇ g to about 350 ⁇ g of the cobalamin compound. In a particularly preferred embodiment, the patient may receive a weekly dosage of about 350 ⁇ g of the cobalamin compound, delivered by once daily nasal administration of 50 ⁇ g of a cobalamin compound.
- a further aspect of the present invention is a composition comprising a cobalamin compound that may be used in a regimen to treat vitamin B 12 deficiency and deficiency related disorders.
- the composition may be used in previously known regimens of treatment for vitamin B 12 deficiency, but preferably is used in the practice of the treatment regimen of the present invention described above.
- a composition of the present invention generally comprises an aqueous solution containing a cobalamin compound.
- the aqueous solution is preferably isotonic.
- the cobalamin may be any of a number of known cobalamin compounds, including for example, cyanocobalamin, hydroxocobalamin (vitamin B 12a ), hydroxocobalamin HCl, sulfate, acetate and other hydroxocobalamin salts, aquacobalamin (vitamin B 12b ), nitrilocobalamin (vitamin B 12c ), methylcobalamin (methyl B 12 ), 5′-deoxyadenosine cobalamin (coenzyme B 12 ), pharmaceutically acceptable salts thereof, chemically modified equivalents thereof, and mixtures thereof.
- cobalamin The selection of the specific form of cobalamin to be used in the composition depends upon a number of factors known to those of skill in the art, including, for example, the composition in which the cobalamin compound is to be mixed or dissolved, the amount or concentration of cobalamin compound desired in the composition, the solubility of the cobalamin compound and the pH of the composition.
- the cobalamin compound is cyanocobalamin USP.
- the cobalamin compound is hydroxocobalamin.
- the concentration of the cobalamin compound in the composition can vary depending upon a number of factors known to those skilled in the art, including, for example, the composition in which the cobalamin compound is to be mixed or dissolved, the solubility of the cobalamin compound, the pH of the composition, the means by which the cobalamin composition is delivered to the nasal mucosa (e.g., using compressed gas or a propellant), the volume of the spray dispensed per application and the desired dosage to be delivered to the patient.
- the cobalamin compound may be present in the composition in a concentration of no more than about 20 weight percent (% w/w), for example, from about 0.0001% w/w to about 20% w/w, preferably from about 0.01% w/w to about 10% w/w, more preferably from about 0.02% w/w to about 1% w/w, still more preferably from about 0.02% w/w to about 0.04% w/w and most preferably about 0.025% w/w.
- % w/w weight percent
- the isotonicity of the composition may generally be achieved and maintained using sodium chloride or another pharmaceutically acceptable isotonicity agent, such as, for example, dextrose, boric acid, sodium tartrate, other organic or inorganic solutes and mixtures thereof.
- the isotonicity agent is typically present in the composition in a concentration sufficient to cause the osmolarity of the composition to be from about 280 mOsmols to about 290 mOsmols ⁇ 50 mOsmols.
- Sodium chloride is generally preferred, particularly if a buffer containing sodium ions is used in the composition, and is typically present in an amount that is physiologically equivalent to the tonicity of the nasal membranes.
- the cobalamin composition of the present invention may further include a pharmaceutically acceptable buffer in order to maintain the desired pH.
- suitable buffers used to adjust and maintain the pH of the composition include acetate, citrate, prolamine, phosphate, carbonate, phthalate, borate, or other pharmaceutically acceptable buffers and mixtures thereof.
- the buffer comprises sodium phosphate.
- the pH of the composition is maintained generally to be compatible with the fluids of the nasal membrane in order to minimize irritation.
- the composition may be maintained at a pH from about 3 to about 11.
- the composition may be maintained at a pH from about 3 to about 6.5, preferably from about 4 to about 6.5, more preferably from about 5 to about 6.5, still more preferably from about 6 to about 6.5, and most preferably about 6.5.
- the composition may be maintained at a pH greater than 6.5, preferably from about 6.5 to about 11, more preferably from about 7 to about 10, still more preferably from about 7 to about 9, even more preferably from about 7 to about 7.7, even more preferably about 7.2, and most preferably about 7.7.
- the concentration of the buffer in the composition will depend upon the selection of the buffer and the desired pH.
- the present composition may also contain various pharmaceutically acceptable additives such as tolerance enhancers (sometimes more specifically referred to as humectants), absorption enhancers (sometimes also referred to as surfactants), preservatives, viscosity modifying agents (e.g., thickening agents), osmolarity adjusters, complexing agents, stabilizers, solubilizers, or any combination thereof.
- tolerance enhancers sometimes more specifically referred to as humectants
- absorption enhancers sometimes also referred to as surfactants
- preservatives e.g., viscosity modifying agents (e.g., thickening agents), osmolarity adjusters, complexing agents, stabilizers, solubilizers, or any combination thereof.
- a tolerance enhancer may be used in order to inhibit drying of the nasal membrane or mucosa.
- a tolerance enhancer may also serve the purpose of inhibiting or relieving irritation of the nasal membranes.
- suitable tolerance enhancers include, for example, humectants such as sorbitol, propylene glycol, glycerol, glycerin, hyaluronan, aloe, mineral oil, vegetable oil, soothing agents, membrane conditioners, sweeteners, and mixtures thereof.
- the selection and concentration of a tolerance enhancer may depend on a number of factors, including, for example, the type and concentration of cobalamin compound being used in the composition. When used, the concentration of the tolerance enhancer in the composition will typically be in amounts from about 0.01% w/w to about 20% w/w.
- a surfactant or absorption enhancer may also be used in the composition in order to enhance the absorption of the cobalamin compound across the nasal membrane.
- Suitable absorption enhancers include non-ionic, anionic and cationic surfactants. Any of a number of well-known surfactants may be used, including, for example, polyoxyethylene derivatives of fatty acids, partial esters of sorbitol anhydrides, sodium lauryl sulfate, sodium salicylate, oleic acid, lecithin, dehydrated alcohol, Tween (e.g., Tween 20, Tween 40, Tween 60, Tween 80 and the like), Span (e.g., Span 20, Span 40, Span 80 and the like), polyoxyl 40 stearate, polyoxy ethylene 50 stearate, edetate disodium, propylene glycol, glycerol monooleate, fusieates, bile salts, octoxynol and combinations thereof.
- the concentration of the surfactant in the composition will typically be from about 0.1% w/w to about 50% w/w.
- concentrations of sodium salicylate, sodium lauryl sulfate and edetate disodium may be from about 0.01% to about 5% w/w of the composition.
- Concentrations of polyoxyl 40 stearate, lecithin, dehydrated alcohol can be from about 0.1% to about 10% w/w of the composition.
- Concentrations of oleic acid can be from about 0.01% to about 5% w/w of the composition.
- Concentrations of propylene glycol and Tween 20 can be from about 0.1% to about 25% w/w of the composition.
- a pharmaceutically acceptable thickening agent may also be used in the composition in order to modify the viscosity of the composition.
- Numerous pharmaceutically acceptable thickening agents are well-known and include, for example, methyl cellulose, xanthan gum, carboxymethyl cellulose, hydroxypropyl cellulose, carbomer, polyvinyl alcohol, alginates, acacia, chitosans and combinations thereof.
- the concentration of the thickening agent will depend upon the agent selected and the viscosity desired. Such agent may be present in the composition at a concentration of from about 0.1% w/w to about 20% w/w.
- a preservative may also be employed to increase the shelf-life of the composition.
- a number of well-known and pharmaceutically acceptable preservatives may be used in the present composition, including, for example, parabens, thimerosal, chlorobutanol, benzalkonium chloride, or benzyl alcohol and combinations thereof.
- Other ingredients which extend shelf life can be added such as for example, antioxidants.
- antioxidants include sodium metabisulfite, potassium metabisulfite, ascorbyl palmitate and other pharmaceutically acceptable antioxidants.
- the antioxidant will be present in the composition in a concentration of from about 0.01% w/w to about 5% w/w.
- Benzyl alcohol and benzalkonium chloride are preferred preservatives.
- a suitable concentration of preservative will depend on a number of factors, including, for example, the particular preservative selected, the intended shelf-life of the composition, and the results of preservative effectiveness and minimum preservative studies. When used, the concentration of the preservative in the composition will typically be from about 0.001% w/w to about 5% w/w, preferably from about 0.01% w/w to about 1% w/w and more preferably from about 0.02% w/w to about 0.4% w/w.
- the cobalamin composition comprises sodium chloride, 0.649% w/w (0.11M); sodium phosphate, monobasic, anhydrous, 0.19% w/w (0.016M); benzyl alcohol, NF, 0.366% w/w (0.034M); sodium hydroxide, NF, 0.04% w/w (0.010M); benzalkonium chloride, 50%, NF, 0.02% w/w; cyanocobalamin, USP, 0.025% w/w (0.00018M); in purified water, USP, 98.71% w/w.
- the cobalamin composition may be formulated to be a sterile, preservative-free composition. While preservatives may extend the shelf life of a composition, they may also cause or exacerbate irritation to the nasal membranes. Furthermore, because of the frequency with which the composition of the present invention is preferably administered, a bottle of typical volume for storing and dispensing the composition will likely be emptied by the patient before the occurrence of the degradation, spoilage, or bacterial growth that a preservative is meant to prevent.
- the cobalamin composition is preservative-free and comprises sodium chloride, 0.649% w/w (0.11M); sodium phosphate, monobasic, anhydrous, 0.19% w/w (0.016M); sodium hydroxide, NF, 0.04% w/w (0.10M); cyanocobalamin, USP, 0.025% w/w (0.00018M); in purified water, USP, 99.096% w/w.
- composition may be prepared by methods known to those of skill in the art, including by combining or mixing the components according to generally accepted procedures.
- the selected components may be simply mixed in a blender or other standard mixing machine to produce a concentrated composition which is then adjusted to the final concentration by the addition of water.
- Suitable containers and metering valves for dispensing the cobalamin composition according to the methods of the invention are available commercially and are known to those of skill in the art.
- the container and valve system used to deliver the cobalamin composition may incorporate any of the conventional aerosol formation techniques.
- a low boiling liquid hydrocarbon such as, for example, butane, isobutane, propane, and other low boiling hydrocarbons in either pure or mixed forms
- halohydrocarbon fluorocarbons (such as, for example, FC-152A), chlorofluorocarbons (such as Freon or Freon like fluorocarbons, such as, for example, CFC-11, CFC-12 and CFC-114), and hydrofluorocarbons, also referred to as hydrofluoroalkanes (such as, for example, HFA-134a and HFA-227) are vaporized to exert a pressure and force the composition through the metering valve.
- the cobalamin composition is stored for administration in a container or bottle including a pump and metering valve adapted for delivery of a metered spray of the composition and designed to inhibit or prevent degradation or spoilage of and bacterial growth in the composition contained therein.
- a container or bottle including a pump and metering valve adapted for delivery of a metered spray of the composition and designed to inhibit or prevent degradation or spoilage of and bacterial growth in the composition contained therein.
- Examples of such a container are the spray pump bottles produced by and available from Pfeiffer (Advanced Preservative Free System) and from Valois (VPY).
- the study comprised twenty-five subjects, ages 18-85, with a history of documented vitamin B 12 deficiency who had previously been receiving maintenance intramuscular (IM) injections of B 12 .
- the purpose of this study was to determine whether as an alternative to IM injections, one daily administration of a 0.025% by weight cobalamin composition is sufficient to sustain an efficacious level of B 12 in place of IM therapy and, thereby, maintain a serum B 12 level within the therapeutic range of greater than about 200 ng/L.
- an aqueous isotonic composition containing a cobalamin compound was provided to the subjects to allow them to dose themselves at home with one daily intranasal (IN) administration comprising two puffs or sprays of B 12 (cobalamin).
- IN intranasal
- B 12 cobalamin
- Subjects with chronic B 12 deficiencies were treated with intramuscular (IM) injections every 4-8 weeks.
- IM intramuscular
- the primary efficacy endpoint is the average of the vitamin B 12 levels from Visits 3, 4, 5 and 6 relative to the B 12 levels at Visit 1.
- the ratio of each post baseline value to baseline was calculated, and the repeated measures model was used to calculate the means of the ratios at each visit.
- the estimate statement (statement 1) provided an estimate of the average of the ratios across visits 3, 4, 5 and 6 and the confidence interval around that average.
- Visit 1 and Visit 2 will not correspond to the same relative week.
- the following schedule describes the actual times:
- Visit #1 (V1)—Midpoint between IM injections (anywhere from 2 to 4 weeks post IM therapy).
- Visit #2 (V2)—Termination of IM therapy (anywhere from 4 to 8 weeks post IM therapy). This is the point at which the next IM injection would have been given, but for the fact that the study participants began intranasal therapy instead.
- the average (standard deviation) age of the 25 subjects was 59.8 (15.5) years, ranging from 28.0 to 82.6 years. Seventeen (68.0%) of the subjects were female. Twenty-one (84.0%) were Caucasian and four (16.0%) were African American. The general pattern was an initial decline from Visit #1 to Visit #2 and a steady increase in the last four visits (Visits #3-#6), although there were exceptions.
- the mean B 12 value, range, and standard deviation at each visit are summarized in Table 2, and the means and their 95% confidence intervals are also shown in FIG. 1 .
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Otolaryngology (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Anesthesiology (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pulmonology (AREA)
- Mechanical Engineering (AREA)
- Diabetes (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/506,148 US20070111964A1 (en) | 2005-08-17 | 2006-08-17 | Vitamin B12 nasal spray and method of use |
US12/618,099 US9186374B2 (en) | 2005-08-17 | 2009-11-13 | Vitamin B12 nasal spray and method of use |
US14/738,417 US10251908B2 (en) | 2005-08-17 | 2015-06-12 | Vitamin B12 nasal spray and method of use |
US14/878,430 US10052344B2 (en) | 2005-08-17 | 2015-10-08 | Vitamin B12 nasal spray and method of use |
US16/296,876 US20190216842A1 (en) | 2005-08-17 | 2019-03-08 | Vitamin b12 nasal spray and method of use |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US70920005P | 2005-08-17 | 2005-08-17 | |
US11/506,148 US20070111964A1 (en) | 2005-08-17 | 2006-08-17 | Vitamin B12 nasal spray and method of use |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/618,099 Continuation US9186374B2 (en) | 2005-08-17 | 2009-11-13 | Vitamin B12 nasal spray and method of use |
Publications (1)
Publication Number | Publication Date |
---|---|
US20070111964A1 true US20070111964A1 (en) | 2007-05-17 |
Family
ID=37758389
Family Applications (5)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/506,148 Abandoned US20070111964A1 (en) | 2005-08-17 | 2006-08-17 | Vitamin B12 nasal spray and method of use |
US12/618,099 Active 2028-04-07 US9186374B2 (en) | 2005-08-17 | 2009-11-13 | Vitamin B12 nasal spray and method of use |
US14/738,417 Active US10251908B2 (en) | 2005-08-17 | 2015-06-12 | Vitamin B12 nasal spray and method of use |
US14/878,430 Active US10052344B2 (en) | 2005-08-17 | 2015-10-08 | Vitamin B12 nasal spray and method of use |
US16/296,876 Abandoned US20190216842A1 (en) | 2005-08-17 | 2019-03-08 | Vitamin b12 nasal spray and method of use |
Family Applications After (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/618,099 Active 2028-04-07 US9186374B2 (en) | 2005-08-17 | 2009-11-13 | Vitamin B12 nasal spray and method of use |
US14/738,417 Active US10251908B2 (en) | 2005-08-17 | 2015-06-12 | Vitamin B12 nasal spray and method of use |
US14/878,430 Active US10052344B2 (en) | 2005-08-17 | 2015-10-08 | Vitamin B12 nasal spray and method of use |
US16/296,876 Abandoned US20190216842A1 (en) | 2005-08-17 | 2019-03-08 | Vitamin b12 nasal spray and method of use |
Country Status (3)
Country | Link |
---|---|
US (5) | US20070111964A1 (fr) |
JP (1) | JP2009504767A (fr) |
WO (1) | WO2007022345A2 (fr) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20120015880A1 (en) * | 2008-12-22 | 2012-01-19 | Seymour Fein | Intranasal desmopressin administration |
US20150320787A1 (en) * | 2006-05-30 | 2015-11-12 | Orahealth Corp. | Cobalamin compositions and methods for treating or preventing mucositis |
US9539302B2 (en) | 2009-06-18 | 2017-01-10 | Allergan, Inc. | Safe desmopressin administration |
CN111671912A (zh) * | 2020-06-22 | 2020-09-18 | 上海上药第一生化药业有限公司 | 含腺苷钴胺的组合物、冻干粉及其制备方法、注射用药物 |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7404489B1 (en) | 2003-03-04 | 2008-07-29 | Qol Medical, Llc | Cyanocobalamin low viscosity aqueous formulations for intranasal delivery |
US20070111964A1 (en) | 2005-08-17 | 2007-05-17 | Fleming And Company, Pharmaceuticals | Vitamin B12 nasal spray and method of use |
CN101600729A (zh) * | 2006-06-23 | 2009-12-09 | 帕尔医疗公司 | 用于鼻内递送的氰钴胺低粘度水性制剂 |
ES2686299T3 (es) * | 2010-10-29 | 2018-10-17 | Troikaa Pharmaceuticals Ltd | Composiciones nasales de vitamina B12 |
NL2010550C2 (en) | 2012-11-30 | 2014-06-04 | Klaas Alouis Riepma | An intranasal pharmaceutical composition containing vitamin b12. |
JP5797227B2 (ja) * | 2013-05-21 | 2015-10-21 | パル ファーマシューティカル, インコーポレーテッド | 鼻内送達用シアノコバラミン低粘度水性製剤 |
ITUB20153950A1 (it) * | 2015-09-28 | 2017-03-28 | Tred Srl | Dispositivo nasale in grado di attivare il riflesso rino-palatale per l'igienizzazione rinofaringea |
DK3698791T3 (da) * | 2017-02-02 | 2024-01-15 | Otolanum Ag | Intranasal sammensætning, der omfatter betahistin |
EP3589269B1 (fr) * | 2017-03-02 | 2021-04-07 | Dutch Renewable Energy B.V. | Administration intranasale de substances physiologiquement actives |
CN112969450B (zh) | 2018-09-20 | 2023-05-30 | 阿卡蒂亚药品公司 | 卡贝缩宫素药物产品及用于制备其的方法 |
WO2020061414A1 (fr) | 2018-09-20 | 2020-03-26 | Levo Therapeutics, Inc. | Formulations intranasales stables de carbétocine |
Citations (49)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2703303A (en) * | 1950-02-25 | 1955-03-01 | Merck & Co Inc | Production of l. l. d-active substances by streptomyces |
US2703302A (en) * | 1952-12-08 | 1955-03-01 | Merck & Co Inc | Vitamin b12-active composition and process of preparing same |
US2746796A (en) * | 1953-08-05 | 1956-05-22 | Pharma Craft Corp | Metering valve aerosol bottle |
US2914222A (en) * | 1957-05-20 | 1959-11-24 | Meshberg Philip | Aerosol package |
US2951017A (en) * | 1957-06-27 | 1960-08-30 | Distillers Co Yeast Ltd | Cobalamin producing fermentation process |
US3000793A (en) * | 1957-01-22 | 1961-09-19 | Merck & Co Inc | Production of cobalamins |
US3018225A (en) * | 1959-03-09 | 1962-01-23 | Merck & Co Inc | Production of vitamin b12 |
US3057851A (en) * | 1959-04-13 | 1962-10-09 | Armour Pharma | Process for preparing vitamin b12 |
US3120509A (en) * | 1959-12-16 | 1964-02-04 | Hoffmann La Roche | Process for the manufacture of vitamins of the group b |
US3282781A (en) * | 1960-11-25 | 1966-11-01 | Merck & Co Inc | Inhalant compositions |
US3548057A (en) * | 1969-04-29 | 1970-12-15 | Merck & Co Inc | Topical administration of vitamin b12 |
US3577537A (en) * | 1970-03-09 | 1971-05-04 | Merck & Co Inc | Topical administration of vitamin b-12 |
US3584115A (en) * | 1968-05-31 | 1971-06-08 | Arthur Ira Gebhart | Method of applying visible aerosol compositions |
US3957966A (en) * | 1972-05-19 | 1976-05-18 | Gaf Corporation | Stabilized vitamin food coatings |
US4174295A (en) * | 1976-08-13 | 1979-11-13 | Montedison S.P.A. | Aerosol propellant compositions |
US4269835A (en) * | 1979-12-13 | 1981-05-26 | Whittle Barry J | Nasal composition for relieving nasal distress |
US4525341A (en) * | 1984-04-09 | 1985-06-25 | Mayor Pharmaceutical Laboratories, Inc. | Method of administering vitamins |
US4624965A (en) * | 1984-11-15 | 1986-11-25 | Nastech Pharmaceutical Co., Inc. | Novel method of administering anti-nausea and anti-emetic pharmaceutical agents and novel dosage forms containing same |
US4724231A (en) * | 1985-04-16 | 1988-02-09 | Nastech Pharmaceutical, Inc. | Nasel compositions containing vitamin B12 |
US4727231A (en) * | 1985-10-01 | 1988-02-23 | Doryokuro Kakunenryo Kaihatsu Jigyodan | Method and apparatus for denitration of nitrate solution by microwave heating |
US4749700A (en) * | 1984-10-23 | 1988-06-07 | Nastech Pharmaceutical Co, Inc. | Novel methods of administering antihistamines, antinausea and antiemetic pharmaceutical agents and novel dosage forms containing same |
US5112804A (en) * | 1987-04-01 | 1992-05-12 | Temple University Of The Commonwealth System Of Higher Education | Pharmaceutical composition and method of intranasal administration |
US5508282A (en) * | 1993-05-17 | 1996-04-16 | Jeffrey Tulin-Silver | Composition and method for treating acute or chronic rhinosinusitis |
US5797390A (en) * | 1996-03-06 | 1998-08-25 | Mcsoley; Thomas E. | Nasal inhaler having a directed spray pattern |
US5801161A (en) * | 1993-12-20 | 1998-09-01 | Merkus; Franciscus W. H. M. | Pharmaceutical composition for the intranasal administration of hydroxocobalamin |
US5840278A (en) * | 1997-02-20 | 1998-11-24 | Coleman; Thomas | Nasal spray having a mineral vitamin component, a mineral component and aloe vera |
US5925625A (en) * | 1994-05-13 | 1999-07-20 | Merkus; Franciscus W. H. M. | Pharmaceutical composition for the intranasal administration of hydroxocobalamin |
US6004560A (en) * | 1998-11-16 | 1999-12-21 | Hsu; Wu-Ching | Nasal spray (drop) for treating fever/cold, and its preparation |
US6017963A (en) * | 1995-11-14 | 2000-01-25 | Euro-Celtique, S.A. | Formulation for intranasal administration |
US6080783A (en) * | 1998-09-01 | 2000-06-27 | Gum Tech International, Inc. | Method and composition for delivering zinc to the nasal membrane |
US6103218A (en) * | 1997-04-23 | 2000-08-15 | Brucker; Donald | Therapeutic nasal spray administered composition containing feverfew |
US6180663B1 (en) * | 1999-12-03 | 2001-01-30 | Stanley Lang | Therapeutic nasal inhalant |
US6248363B1 (en) * | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
US6255294B1 (en) * | 1998-12-28 | 2001-07-03 | Allergy Limited | Cyanocobalamin (vitamin B12) treatment in allergic disease |
US6297244B1 (en) * | 1997-10-20 | 2001-10-02 | Dainippon Pharmaceutical Co., Ltd. | Stable drug composition |
US6333044B1 (en) * | 1991-07-22 | 2001-12-25 | Recordati, S.A. Chemical And Pharmaceutical Company | Therapeutic compositions for intranasal administration which include KETOROLAC® |
US6428805B1 (en) * | 1998-08-26 | 2002-08-06 | Teijin Limited | Powdery nasal compositions |
US6528496B1 (en) * | 1992-12-29 | 2003-03-04 | Allen Robert H | Compositions treating, preventing or reducing elevated metabolic levels |
US20030059440A1 (en) * | 1998-09-01 | 2003-03-27 | Tim Clarot | Composition and method for moisturizing nasal tissue |
US20030144198A1 (en) * | 2001-09-28 | 2003-07-31 | Collins Douglas A. | Coadministration of transport protein with conjugated cobalamin to deliver agents |
US20030225044A1 (en) * | 2002-06-03 | 2003-12-04 | Bachman Stephen E. | Method to increase serum levels of vitamins in animals including humans |
US6660293B2 (en) * | 2001-06-29 | 2003-12-09 | Everett Laboratories, Inc. | Compositions and methods for prophylactic and therapeutic supplementation of nutrition in subjects |
US20040057907A1 (en) * | 2002-09-23 | 2004-03-25 | Leonard Mackles | Dri-nasal sprays |
US20040219107A1 (en) * | 2002-09-16 | 2004-11-04 | Tim Clarot | System for delivering a composition to the nasal membrane and method of using same |
US20050019411A1 (en) * | 2001-10-18 | 2005-01-27 | Paolo Colombo | Powder for nasal administration of drugs |
US6881423B2 (en) * | 1996-02-27 | 2005-04-19 | Teijin Limited | Powdery composition for nasal administration |
US20050226906A1 (en) * | 2004-04-08 | 2005-10-13 | Micro Nutrient, Llc | Nutrient system for individualized responsive dosing regimens |
US20050226907A1 (en) * | 2004-04-08 | 2005-10-13 | Moneymaker Ricky D | Pharmanutrient composition(s) and system(s) for individualized, responsive dosing regimens |
US20050232981A1 (en) * | 2004-04-15 | 2005-10-20 | Ben-Sasson Shmuel A | Compositions capable of facilitating penetration across a biological barrier |
Family Cites Families (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3120508A (en) | 1959-08-20 | 1964-02-04 | Hoechst Ag | Process for the manufacture of waterinsoluble azo-dyestuffs |
US3547138A (en) | 1968-09-19 | 1970-12-15 | Gen Electric | Fluidic high to low frequency converter circuit |
US3957968A (en) | 1973-08-20 | 1976-05-18 | Colgate-Palmolive Company | Dentifrices containing flat flakes of alpha-alumina |
IT1164227B (it) | 1983-05-13 | 1987-04-08 | Angeli Inst Spa | Composizione farmaceutica atta alla somministrazione nasale di sali quaternari d'ammonio ed attivita' anticolinergica |
DE3323389A1 (de) | 1983-06-29 | 1985-01-10 | B. Braun Melsungen Ag, 3508 Melsungen | Auf schleimhaeute des mundes, der nase und/oder des rachens wirkende arzneimittel auf der basis von heparin und tensiden |
US4523341A (en) | 1983-12-12 | 1985-06-18 | Queen Carl J | Bathing cabinet with transporter cart |
DE3682862D1 (de) | 1985-04-16 | 1992-01-23 | Nastech Pharm Co | Aerosolmittel zur nasenverstaeubung von vitamin b 12. |
US4782047A (en) | 1986-05-22 | 1988-11-01 | Syntex Pharmaceuticals International Ltd. | Aqueous steroid formulations for nasal administration |
US4959176A (en) | 1988-04-29 | 1990-09-25 | Beckman Instruments, Inc. | High resolution non corrosive amino acid analysis buffer solutions |
JPH03129153A (ja) | 1989-10-12 | 1991-06-03 | Kiyomi Okamoto | 無段変速装置 |
US5277311A (en) | 1991-12-20 | 1994-01-11 | Smiths Industries Medical Systems, Inc. | Needle assembly holder with rotatable safety sheath member and method of effecting proper alignment of a cannula using such needle assembly holder |
JPH05170663A (ja) | 1991-12-20 | 1993-07-09 | Mitsubishi Kasei Corp | カルシトニン点鼻用医薬組成物 |
US5825625A (en) | 1996-05-20 | 1998-10-20 | Hewlett-Packard Company | Heat conductive substrate mounted in PC board for transferring heat from IC to heat sink |
AU724728B2 (en) | 1997-07-03 | 2000-09-28 | Pfizer Inc. | Pharmaceutical compositions containing eletriptan hemisulphate and caffeine |
US6406730B1 (en) | 1998-12-01 | 2002-06-18 | Carl E. Banyard | Process for producing low acid food products |
FR2787029A1 (fr) | 1998-12-09 | 2000-06-16 | Biovector Therapeutics | Utilisation dans une composition pharmaceutique pour l'administration par voie nasale de vitamine b12 pour la delivrance d'agents actifs au systeme nerveux central |
WO2001013322A1 (fr) | 1999-08-17 | 2001-02-22 | Image Therm Engineering | Systeme d'analyse et de caracterisation des donnees d'un nuage d'aerosol |
EP1210580B1 (fr) | 1999-08-17 | 2009-08-05 | Proveris Scientific Corporation | Procede d'acquisition de donnees de pulverisation |
WO2002024165A2 (fr) | 2000-09-20 | 2002-03-28 | Nycomed Pharma As | Preparation d'emulsions et de concentres de ces dernieres |
US6745760B2 (en) | 2001-05-15 | 2004-06-08 | Trudell Medical International | Medicament applicator |
DK1506464T3 (da) | 2001-06-21 | 2010-05-03 | Proveris Scient Corp | Præcist positionsstyret aktiveringssystem |
JP4164730B2 (ja) | 2001-07-30 | 2008-10-15 | 東洋紡績株式会社 | 選択分離膜 |
US20060074034A1 (en) | 2001-09-17 | 2006-04-06 | Collins Douglas A | Cobalamin mediated delivery of nucleic acids, analogs and derivatives thereof |
US6911434B2 (en) | 2002-02-04 | 2005-06-28 | Corixa Corporation | Prophylactic and therapeutic treatment of infectious and other diseases with immunoeffector compounds |
US20040034042A1 (en) * | 2002-08-14 | 2004-02-19 | Masao Tsuji | Preservative composition |
US20040109826A1 (en) | 2002-12-06 | 2004-06-10 | Dey, L.P. | Stabilized albuterol compositions and method of preparation thereof |
US6685421B1 (en) | 2003-01-02 | 2004-02-03 | Charles N. Reeves | Hitch-mounted lift assembly |
DE10300719A1 (de) | 2003-01-11 | 2004-07-22 | Basf Ag | Verbessertes Verfahren zur Herstellung von Vitamin B12 |
US7404489B1 (en) * | 2003-03-04 | 2008-07-29 | Qol Medical, Llc | Cyanocobalamin low viscosity aqueous formulations for intranasal delivery |
WO2005004895A2 (fr) | 2003-06-09 | 2005-01-20 | Nastech Pharmaceutical Company Inc. | Compositions et procedes d'une meilleure administration d'hormone de croissance par voie muqueuse |
JP2005016262A (ja) | 2003-06-27 | 2005-01-20 | Kyocera Corp | 太陽電池モジュール取付構造体 |
US20060127320A1 (en) | 2004-05-10 | 2006-06-15 | Nastech Pharmaceutical Company Inc. | Method of delivering parathyroid hormone to a human |
US20060046969A1 (en) | 2004-08-25 | 2006-03-02 | Aegis Therapeutics Llc | Antibacterial compositions for drug administration |
US20070111964A1 (en) | 2005-08-17 | 2007-05-17 | Fleming And Company, Pharmaceuticals | Vitamin B12 nasal spray and method of use |
-
2006
- 2006-08-17 US US11/506,148 patent/US20070111964A1/en not_active Abandoned
- 2006-08-17 WO PCT/US2006/032127 patent/WO2007022345A2/fr active Application Filing
- 2006-08-17 JP JP2008527134A patent/JP2009504767A/ja active Pending
-
2009
- 2009-11-13 US US12/618,099 patent/US9186374B2/en active Active
-
2015
- 2015-06-12 US US14/738,417 patent/US10251908B2/en active Active
- 2015-10-08 US US14/878,430 patent/US10052344B2/en active Active
-
2019
- 2019-03-08 US US16/296,876 patent/US20190216842A1/en not_active Abandoned
Patent Citations (52)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2703303A (en) * | 1950-02-25 | 1955-03-01 | Merck & Co Inc | Production of l. l. d-active substances by streptomyces |
US2703302A (en) * | 1952-12-08 | 1955-03-01 | Merck & Co Inc | Vitamin b12-active composition and process of preparing same |
US2746796A (en) * | 1953-08-05 | 1956-05-22 | Pharma Craft Corp | Metering valve aerosol bottle |
US3000793A (en) * | 1957-01-22 | 1961-09-19 | Merck & Co Inc | Production of cobalamins |
US2914222A (en) * | 1957-05-20 | 1959-11-24 | Meshberg Philip | Aerosol package |
US2951017A (en) * | 1957-06-27 | 1960-08-30 | Distillers Co Yeast Ltd | Cobalamin producing fermentation process |
US3018225A (en) * | 1959-03-09 | 1962-01-23 | Merck & Co Inc | Production of vitamin b12 |
US3057851A (en) * | 1959-04-13 | 1962-10-09 | Armour Pharma | Process for preparing vitamin b12 |
US3120509A (en) * | 1959-12-16 | 1964-02-04 | Hoffmann La Roche | Process for the manufacture of vitamins of the group b |
US3282781A (en) * | 1960-11-25 | 1966-11-01 | Merck & Co Inc | Inhalant compositions |
US3584115A (en) * | 1968-05-31 | 1971-06-08 | Arthur Ira Gebhart | Method of applying visible aerosol compositions |
US3548057A (en) * | 1969-04-29 | 1970-12-15 | Merck & Co Inc | Topical administration of vitamin b12 |
US3577537A (en) * | 1970-03-09 | 1971-05-04 | Merck & Co Inc | Topical administration of vitamin b-12 |
US3957966A (en) * | 1972-05-19 | 1976-05-18 | Gaf Corporation | Stabilized vitamin food coatings |
US4174295A (en) * | 1976-08-13 | 1979-11-13 | Montedison S.P.A. | Aerosol propellant compositions |
US4269835A (en) * | 1979-12-13 | 1981-05-26 | Whittle Barry J | Nasal composition for relieving nasal distress |
US4525341A (en) * | 1984-04-09 | 1985-06-25 | Mayor Pharmaceutical Laboratories, Inc. | Method of administering vitamins |
US4749700A (en) * | 1984-10-23 | 1988-06-07 | Nastech Pharmaceutical Co, Inc. | Novel methods of administering antihistamines, antinausea and antiemetic pharmaceutical agents and novel dosage forms containing same |
US4624965A (en) * | 1984-11-15 | 1986-11-25 | Nastech Pharmaceutical Co., Inc. | Novel method of administering anti-nausea and anti-emetic pharmaceutical agents and novel dosage forms containing same |
US4724231A (en) * | 1985-04-16 | 1988-02-09 | Nastech Pharmaceutical, Inc. | Nasel compositions containing vitamin B12 |
US4727231A (en) * | 1985-10-01 | 1988-02-23 | Doryokuro Kakunenryo Kaihatsu Jigyodan | Method and apparatus for denitration of nitrate solution by microwave heating |
US5112804A (en) * | 1987-04-01 | 1992-05-12 | Temple University Of The Commonwealth System Of Higher Education | Pharmaceutical composition and method of intranasal administration |
US6333044B1 (en) * | 1991-07-22 | 2001-12-25 | Recordati, S.A. Chemical And Pharmaceutical Company | Therapeutic compositions for intranasal administration which include KETOROLAC® |
US6528496B1 (en) * | 1992-12-29 | 2003-03-04 | Allen Robert H | Compositions treating, preventing or reducing elevated metabolic levels |
US5508282A (en) * | 1993-05-17 | 1996-04-16 | Jeffrey Tulin-Silver | Composition and method for treating acute or chronic rhinosinusitis |
US5508282C1 (en) * | 1993-05-17 | 2001-01-23 | Tulin Silver Jeffrey | Composition and method for treating acute or chronic rhinosinusitis |
US5801161A (en) * | 1993-12-20 | 1998-09-01 | Merkus; Franciscus W. H. M. | Pharmaceutical composition for the intranasal administration of hydroxocobalamin |
US5925625A (en) * | 1994-05-13 | 1999-07-20 | Merkus; Franciscus W. H. M. | Pharmaceutical composition for the intranasal administration of hydroxocobalamin |
US6017963A (en) * | 1995-11-14 | 2000-01-25 | Euro-Celtique, S.A. | Formulation for intranasal administration |
US6881423B2 (en) * | 1996-02-27 | 2005-04-19 | Teijin Limited | Powdery composition for nasal administration |
US5797390A (en) * | 1996-03-06 | 1998-08-25 | Mcsoley; Thomas E. | Nasal inhaler having a directed spray pattern |
US5840278A (en) * | 1997-02-20 | 1998-11-24 | Coleman; Thomas | Nasal spray having a mineral vitamin component, a mineral component and aloe vera |
US6103218A (en) * | 1997-04-23 | 2000-08-15 | Brucker; Donald | Therapeutic nasal spray administered composition containing feverfew |
US6297244B1 (en) * | 1997-10-20 | 2001-10-02 | Dainippon Pharmaceutical Co., Ltd. | Stable drug composition |
US6428805B1 (en) * | 1998-08-26 | 2002-08-06 | Teijin Limited | Powdery nasal compositions |
US20030059440A1 (en) * | 1998-09-01 | 2003-03-27 | Tim Clarot | Composition and method for moisturizing nasal tissue |
US20050180924A1 (en) * | 1998-09-01 | 2005-08-18 | Tim Clarot | Composition and method for moisturizing nasal tissue |
US6673835B1 (en) * | 1998-09-01 | 2004-01-06 | Zicam Llc | Method and composition for delivering zinc to the nasal membrane |
US6080783A (en) * | 1998-09-01 | 2000-06-27 | Gum Tech International, Inc. | Method and composition for delivering zinc to the nasal membrane |
US6004560A (en) * | 1998-11-16 | 1999-12-21 | Hsu; Wu-Ching | Nasal spray (drop) for treating fever/cold, and its preparation |
US6255294B1 (en) * | 1998-12-28 | 2001-07-03 | Allergy Limited | Cyanocobalamin (vitamin B12) treatment in allergic disease |
US6248363B1 (en) * | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
US6180663B1 (en) * | 1999-12-03 | 2001-01-30 | Stanley Lang | Therapeutic nasal inhalant |
US6660293B2 (en) * | 2001-06-29 | 2003-12-09 | Everett Laboratories, Inc. | Compositions and methods for prophylactic and therapeutic supplementation of nutrition in subjects |
US20030144198A1 (en) * | 2001-09-28 | 2003-07-31 | Collins Douglas A. | Coadministration of transport protein with conjugated cobalamin to deliver agents |
US20050019411A1 (en) * | 2001-10-18 | 2005-01-27 | Paolo Colombo | Powder for nasal administration of drugs |
US20030225044A1 (en) * | 2002-06-03 | 2003-12-04 | Bachman Stephen E. | Method to increase serum levels of vitamins in animals including humans |
US20040219107A1 (en) * | 2002-09-16 | 2004-11-04 | Tim Clarot | System for delivering a composition to the nasal membrane and method of using same |
US20040057907A1 (en) * | 2002-09-23 | 2004-03-25 | Leonard Mackles | Dri-nasal sprays |
US20050226906A1 (en) * | 2004-04-08 | 2005-10-13 | Micro Nutrient, Llc | Nutrient system for individualized responsive dosing regimens |
US20050226907A1 (en) * | 2004-04-08 | 2005-10-13 | Moneymaker Ricky D | Pharmanutrient composition(s) and system(s) for individualized, responsive dosing regimens |
US20050232981A1 (en) * | 2004-04-15 | 2005-10-20 | Ben-Sasson Shmuel A | Compositions capable of facilitating penetration across a biological barrier |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20150320787A1 (en) * | 2006-05-30 | 2015-11-12 | Orahealth Corp. | Cobalamin compositions and methods for treating or preventing mucositis |
US20120015880A1 (en) * | 2008-12-22 | 2012-01-19 | Seymour Fein | Intranasal desmopressin administration |
US9539302B2 (en) | 2009-06-18 | 2017-01-10 | Allergan, Inc. | Safe desmopressin administration |
US11419914B2 (en) | 2009-06-18 | 2022-08-23 | Serenity Pharmaceuticals Llc | Safe desmopressin administration |
CN111671912A (zh) * | 2020-06-22 | 2020-09-18 | 上海上药第一生化药业有限公司 | 含腺苷钴胺的组合物、冻干粉及其制备方法、注射用药物 |
Also Published As
Publication number | Publication date |
---|---|
US9186374B2 (en) | 2015-11-17 |
US20190216842A1 (en) | 2019-07-18 |
US10251908B2 (en) | 2019-04-09 |
US20150272876A1 (en) | 2015-10-01 |
WO2007022345A2 (fr) | 2007-02-22 |
US20100210580A1 (en) | 2010-08-19 |
WO2007022345A3 (fr) | 2009-04-30 |
US20160022726A1 (en) | 2016-01-28 |
US10052344B2 (en) | 2018-08-21 |
JP2009504767A (ja) | 2009-02-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10052344B2 (en) | Vitamin B12 nasal spray and method of use | |
US6702997B2 (en) | Albuterol inhalation solution, system, kit and method for relieving symptoms of pediatric asthma | |
US20080031959A1 (en) | Anti-migraine oral spray formulations and methods | |
JP2003221335A (ja) | 慢性閉塞性肺疾患の症状を緩和するためのアルブテロールおよびイプラトロピウム吸入溶液、システム、キットおよび方法 | |
JPS62500789A (ja) | ビタミンb↓1↓2含有経鼻組成物 | |
CA1317881C (fr) | Compositions en aerosol pour l'administration de la vitamine b__ par voie nasale | |
CA2897432A1 (fr) | Compositions de dnj parenterales stables | |
US9415007B2 (en) | Cyanocobalamin low viscosity aqueous formulations for intranasal delivery | |
CA2656823C (fr) | Formulations aqueuses de faible viscosite de cyanocobalamine pour administration intra-nasale | |
US7229636B1 (en) | Cyanocobalamin low viscosity aqueous formulations for intranasal delivery | |
CN116472033A (zh) | 用于经鼻施用的钴胺素化合物的药物组合物 | |
Feller et al. | Vitamin B 12 nasal spray and method of use | |
US20130338200A1 (en) | Pharmaceutical dosage forms of tizanidine and administration routes thereof | |
JP6097787B2 (ja) | 鼻内送達用シアノコバラミン低粘度水性製剤 | |
AU2014202415B2 (en) | Cyanocobalamin low viscosity aqueous formulations for intranasal delivery | |
CA2863377C (fr) | Formulations aqueuses de faible viscosite de cyanocobalamine pour administration intra-nasale | |
RU2021121189A (ru) | Композиции, устройства и способы для лечения расстройств передозировки и связанных с вознаграждением | |
JP2013227319A (ja) | 鼻内送達用シアノコバラミン低粘度水性製剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |
|
AS | Assignment |
Owner name: ENDO PHARMACEUTICALS INC., PENNSYLVANIA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:PAR PHARMACEUTICAL, INC.;ENDO PAR INNOVATION COMPANY, LLC;REEL/FRAME:043118/0747 Effective date: 20170726 |